Artal Group S.A. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001053906

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedConsumer TiltHigh Turnover how tags are computed

Q1 2024 · 108 positions · Total reported value $3.82B · Top-10 concentration 75.3% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 33.3% · 1 new · 0 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q1 2024 13F filing, Artal Group S.A. disclosed 108 equity positions with a combined reported value of $3.82B. The filing implies a focused portfolio: its ten largest positions account for 75.3% of reported value. HoldingsHub classifies the profile as Mid / Focused / Consumer Tilt / High Turnover.

The largest disclosed positions as of Q1 2024 were CAVA ($1.86B), LXRX ($282.13M), SRRK ($199.97M). By sector, the heaviest allocations are Consumer Discretionary 49.2%, Health Care 35.5%. Versus the prior quarter, allocation shifted toward Consumer Discretionary (+1.4pp) and away from Other (-0.5pp), Health Care (-0.9pp).

Versus the prior quarter, Artal Group S.A. opened 1 new positions, trimmed 0 and fully exited 0, a turnover rate of 33.3% of positions. The portfolio's overlap with the prior quarter was 57% of names.

The largest new positions opened in Q1 2024 were CRNX ($65.09M), MDGL ($29.51M), XBI ($23.72M).

Of the 8 positions fully exited versus the prior quarter, the largest were ARGX ($44.28M), MRTX ($29.38M), HARP ($14.83M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2024)

  • CRNX CRINETICS PHARMACEUTICALS IN · $65.09M
  • MDGL MADRIGAL PHARMACEUTICALS INC · $29.51M
  • XBI SPDR SERIES TRUST · $23.72M
  • VERA VERA THERAPEUTICS INC · $21.82M
  • VKTX VIKING THERAPEUTICS INC · $20.82M
  • MRUS MERUS N V · $20.49M
  • NAMS NEWAMSTERDAM PHARMA COMPANY · $18.92M
  • TNGX TANGO THERAPEUTICS INC · $17.43M

Fully Exited (vs previous quarter)

  • ARGX Argenx S.E. · prev qtr: $44.28M
  • MRTX MIRATI THERAPEUTICS INC · prev qtr: $29.38M
  • HARP HARPOON THERAPEUTICS INC · prev qtr: $14.83M
  • NTRA NATERA INC · prev qtr: $12.53M
  • ROIV ROIVANT SCIENCES LTD · prev qtr: $11.23M
  • SDGR SCHRODINGER INC · prev qtr: $10.74M
  • FUSN FUSION PHARMACEUTICALS INC · prev qtr: $9.66M
  • CBAY CYMABAY THERAPEUTICS INC · prev qtr: $7.17M

Insider Transactions (Form 4)

Latest Artal Group S.A. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-15 Sell CAVA GROUP, INC. 3,000,000 $90.30 SEC filing
2026-04-30 Opt exercise LEXICON PHARMACEUTICALS, INC. 20,421,735 — SEC filing

All insider transactions →

Fund Profile

Artal Group S.A. is an SEC-registered 13F filer. As of Q2 2026 it reported 2 US equity positions with a combined value of $931.12M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 2 positions · $931.12M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: CAVA (CAVA GROUP INC) at 54.9%
  • Average position size: $465.56M

Sector Tilt

  • Consumer Discretionary 54.9%
  • Health Care 45.1%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 added, 1 reduced

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 35.5%
Technology 0.5%
Financials 0.1%
Other 14.4%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 26.51M $1.86B 48.63%
48.63%
Reduce
2 117.55M $282.13M 7.39%
7.39%
Hold
3 11.26M $199.97M 5.24%
5.24%
Hold
4 3.03M $121.69M 3.19%
3.19%
Add
5 2.21M $77.90M 2.04%
2.04%
Add
6 1.32M $77.31M 2.02%
2.02%
Reduce
7 1.42M $69.66M 1.82%
1.82%
Reduce
8 1.39M $65.09M 1.71%
1.71%
New
9 404.78K $63.30M 1.66%
1.66%
Hold
10 2.78M $60.04M 1.57%
1.57%
Reduce
11 1.52M $43.09M 1.13%
1.13%
Add
12 1.32M $42.50M 1.11%
1.11%
Reduce
13 1.92M $40.95M 1.07%
1.07%
Add
14 2.92M $40.21M 1.05%
1.05%
Add
15 419.23K $37.73M 0.99%
0.99%
Hold
16 506.58K $35.52M 0.93%
0.93%
Reduce
17 2.50M $33.30M 0.87%
0.87%
Add
18 3.08M $29.73M 0.78%
0.78%
Reduce
19 110.51K $29.51M 0.77%
0.77%
New
20 8.59M $25.77M 0.68%
0.68%
Hold
21 4.05M $25.00M 0.66%
0.66%
Add
22 1.00M $24.80M 0.65%
0.65%
Add
23 250.00K $23.72M 0.62%
0.62%
New
24 506.02K $21.82M 0.57%
0.57%
New
25 253.86K $20.82M 0.55%
0.55%
New
26 455.08K $20.49M 0.54%
0.54%
New
27 800.00K $18.92M 0.49%
0.49%
New
28 2.19M $17.43M 0.46%
0.46%
New
29 600.00K $17.16M 0.45%
0.45%
Add
30 2.41M $16.23M 0.42%
0.42%
Reduce
31 405.78K $16.09M 0.42%
0.42%
Add
32 1.41M $15.96M 0.42%
0.42%
Add
33 811.72K $14.81M 0.39%
0.39%
New
34 2.51M $13.40M 0.35%
0.35%
Hold
35 237.50K $12.76M 0.33%
0.33%
Reduce
36 801.72K $12.57M 0.33%
0.33%
Add
37 884.21K $12.45M 0.33%
0.33%
New
38 1.01M $11.92M 0.31%
0.31%
Reduce
39 2.83M $11.52M 0.30%
0.30%
Add
40 253.39K $10.91M 0.29%
0.29%
New
41 253.00K $10.62M 0.28%
0.28%
New
42 3.69M $10.58M 0.28%
0.28%
Add
43 502.90K $10.32M 0.27%
0.27%
Reduce
44 152.50K $10.13M 0.27%
0.27%
New
45 4.72M $9.73M 0.26%
0.26%
Hold
46 15.63M $9.07M 0.24%
0.24%
Hold
47 4.75M $9.03M 0.24%
0.24%
Hold
48 177.93K $8.31M 0.22%
0.22%
New
49 1.51M $7.76M 0.20%
0.20%
New
50 2.50M $7.62M 0.20%
0.20%
Hold

FAQ

What did Artal Group S.A. buy in 2024-Q1?

In its 2024-Q1 13F filing, Artal Group S.A. reported 108 equity positions worth $3.82B in aggregate; its largest disclosed positions were CAVA ($1.86B), LXRX ($282.13M), SRRK ($199.97M).

How large is Artal Group S.A.'s portfolio?

Artal Group S.A. reported $3.82B of long equity holdings across 108 positions as of 2024-Q1. Top-10 holdings account for 75.3% of reported value.

What is Artal Group S.A.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Consumer Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/artal/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →